Pakzad-Vaezi, Kaivon <br/><br/>
Vascular endothelial growth factor inhibitor use and treatment approach for choroidal neovascularization secondary to pathologic myopia.  [electronic resource] 

 -  Expert opinion on biological therapy  07 2016 
 - 873-81 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1744-7682 
<br/><br/><label>Standard No.: </label>10.1517/14712598.2016.1167868  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiogenesis Inhibitors--administration & dosage<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Choroidal Neovascularization--drug therapy<br/>Clinical Trials as Topic--methods<br/>Female<br/>Humans<br/>Intravitreal Injections<br/>Myopia--complications<br/>Ranibizumab--administration & dosage<br/>Receptors, Vascular Endothelial Growth Factor--administration & dosage<br/>Recombinant Fusion Proteins--administration & dosage<br/>Treatment Outcome<br/>Vascular Endothelial Growth Factor A--antagonists & inhibitors<br/>Visual Acuity--drug effects<br/>Wet Macular Degeneration--drug therapy